8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2020

 

 

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38942   32-0595345
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

10628 Science Center Drive, Suite 250

San Diego, California 92121

(Address of principal executive offices)

Registrant’s telephone number, including area code: (858) 900-2660

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange
on which registered

Common stock, par value $0.001 per share   ARCT   The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 5, 2020, Arcturus Therapeutics Holdings Inc. (the “Company”) held its annual meeting of stockholders (the “Meeting”). The total number of shares entitled to vote at the Meeting was 15,156,989 and there were present at the Meeting, in person or by proxy, 11,692,374 shares, which constituted a quorum for the Meeting.

At the Meeting, the stockholders voted:

(1) for the election of Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet and Karah Parschauer to the Company’s Board of Directors;

(2) for the approval of the Company’s 2020 Employee Stock Purchase Plan;

(3) for the approval of the Company’s Amended & Restated 2019 Omnibus Equity Incentive Plan (the “Amended and Restated Omnibus Plan”) which, among other things, increases the maximum number of shares of common stock reserved for delivery under the plan by 3,150,000 shares; and

(4) for the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2020.

The final results of the stockholder votes at the Meeting are set forth below:

Proposal No. 1

 

     For      Withhold      Broker
Non-Votes
 

Approval of the election of the following individuals as directors of the Company, as provided

in Proposal Number 1 of the Proxy Statement:

        

(1) Dr. Peter Farrell

     9,092,938        74,407        2,525,029  

(2) Joseph E. Payne

     9,103,901        63,444        2,525,029  

(3) Andy Sassine

     9,102,933        64,412        2,525,029  

(4) James Barlow

     9,093,123        74,222        2,525,029  

(5) Dr. Edward W. Holmes

     9,113,491        53,854        2,525,029  

(6) Dr. Magda Marquet

     9,103,911        63,434        2,525,029  

(7) Karah Parschauer

     9,098,600        68,745        2,525,029  

Proposal No. 2

 

     For      Against      Abstain      Broker
Non-Votes
 

Approval of the Company’s 2020 Employee Stock Purchase Plan, as provided in

Proposal Number 2 of the Proxy Statement:

     9,156,041        8,703        2,601        2,525,029  

Proposal No. 3

 

     For      Against      Abstain      Broker
Non-Votes
 

Approval of the Company’s Amended and Restated Omnibus Plan, as provided in

Proposal Number 3 of the Proxy Statement:

     8,425,865        736,062        5,418        2,525,029  

Proposal No. 4

 

     For      Against      Abstain      Broker
Non-Votes
 

Approval of the ratification of the appointment of Ernst & Young LLP as the Company’s

independent registered public accounting firm for the year ending December 31, 2020,

as provided in Proposal Number 4 of the Proxy Statement:

     11,644,555        12,957        34,862        N/A  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Arcturus Therapeutics Holdings Inc.
Date: June 9, 2020    
    By:   /s/ Joseph E. Payne
    Name:   Joseph E. Payne
    Title:   Chief Executive Officer